BioSpace News Archive

Drug Development

Sumitomo, Otsuka’s Schizophrenia Candidate Fails Phase III Trials

Ulotaront failed to meet primary endpoints in two studies. The companies said high COVID-19 placebo effect “may have masked molecule’s therapeutic effect” and plan to discuss next steps with the FDA.

July 31, 2023
·
2 min read
·
Kate Goodwin
Policy

House Republicans Propose Drug Shortage Legislation After Gutting Democrats’ Bill

Amid U.S. shortages in crucial drugs, House Republicans have filed their own draft bill that seeks to increase the accountability of the FDA and provide more flexibility for generics manufacturers.

July 31, 2023
·
2 min read
·
Tristan Manalac
Opinion: Biotechs’ Career Sites Leave Much to Be Desired

A survey of 34 biotech websites reveals that the industry fails to provide quality information to help prospective job candidates understand why they should choose one company over another.

July 31, 2023
·
6 min read
·
James Ellis
Apellis Eye Injection Treatment Flagged for Safety Issues

Syfovre has been linked to rare cases of eye inflammation that could lead to blinding, though Apellis’ review so far has found no connection between the treatment and the complications.

July 31, 2023
·
2 min read
·
Tristan Manalac
Early-Stage Biopharma Funding to Drop 40% This Year: Report

Seed and Series A funding are set to drop this year as investors are looking for more advanced, less risky deals, according to an industry analysis from HSBC.

July 31, 2023
·
2 min read
·
Tristan Manalac
Policy

How the FTC’s Proposed Merger Guidelines Might Affect Biopharma

The Federal Trade Commission seeks to codify its heavier-handed approach, already displayed by its actions regarding Amgen’s acquisition of Horizon, among other deals.

July 31, 2023
·
4 min read
·
Adrianna Nine
Opinion: Is the Biotech Winter Beginning to Thaw?

The industry may not have fully rebounded to the highs seen a couple of years ago, but there are sure signs of spring in the air.

July 31, 2023
·
6 min read
·
Lindsay A. Rosenwald
Biotech Beach

Kernel Introduces Flow2: Revolutionary Advanced Neuroimaging Technology Enabling Precision Neuromedicine

Kernel, a pioneer in neuroimaging technology, is proud to unveil its groundbreaking Flow2 system, a major leap forward in the field of functional neuroimaging.

July 31, 2023
·
2 min read
Business

Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority

Aytu BioPharma, Inc. and Medomie Pharma Ltd, today announced the signing of an exclusive collaboration, distribution and supply agreement for Aytu’s Adzenys XR-ODT® and Cotempla XR-ODT® product lines.

July 31, 2023
·
4 min read
Business

DSS Inc. Announces Distribution Date of August 8, 2023 for Spinoff of Impact BioMedical Inc.DSS Shareholders of Record on July 10, 2023 to Receive Four Shares of Impact Biomedical Inc. for Every One Share of DSS, Inc.

DSS, Inc. announced today the distribution date for the previously announced stock dividend of Impact BioMedical Inc. DSS Inc. shareholders of record on July 10, 2023 will be entitled to four (4) shares of Impact Biomedical Inc. for every one (1) share of DSS to be distributed on August 8, 2023.

July 31, 2023
·
3 min read